Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
benazepril + losartan
- Development stage
- Unknown
- Lead developer
- Novartis
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This is a combination of benazepril (an angiotensin-converting enzyme inhibitor) and losartan (an angiotensin II receptor blocker). Both medications are used to treat hypertension but through different mechanisms. Benazepril works by blocking a substance in the body that causes blood vessels to tighten, while losartan blocks the action of angiotensin II. Using these medications together is generally not recommended as standard practice due to increased risk of side effects including low blood pressure, kidney function impairment, and other adverse effects.
02
Targets
AGTR1 (Angiotensin II Type-1 receptor)ACE (Angiotensin Converting Enzyme)
Beyond the preview
Go deeper on benazepril + losartan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on benazepril + losartan.